[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Atea Pharmaceuticals, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100649040","phase-1-study-of-at-587-in-healthy-subjects-100649040",false,"NCT07728487","Study of AT-587 in Healthy Subjects","A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants","Inclusion Criteria:\n\n* Body mass index (BMI) of 18-29 kg\u002Fm2\n* Must agree to use protocol-specified methods of contraception\n* Negative pregnancy test\n* Willing to comply with the study requirements and to provide written informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Abuse of alcohol or drugs\n* Use of other investigational drugs within 30 days of dosing\n* Other clinically significant medical conditions",true,"ALL","18 Years","65 Years",{"count":21,"type":22},62,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects",[28],"Hepatitis E","RECRUITING","2026-07-22",{"date":32,"type":33},"2026-07-27","ACTUAL",{"date":35,"type":33},"2026-07-13",{"date":37,"type":22},"2026-12",{"name":39,"class":40},"Atea Pharmaceuticals, Inc.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100617109","phase-1-drug-drug-interaction-study-of-bemnifosbuvirruzasvir-bemrzr-and-buprenorphinenaloxone-or-methadone-100617109","NCT07314346","Drug-drug Interaction Study of Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone","A Phase 1, Open-Label, Two-Part, Single-Sequence Study to Evaluate the Effect of Multiple Oral Doses of BEM\u002FRZR FDC on the Pharmacokinetics of Buprenorphine\u002FNaloxone or Methadone in Participants on Stable Maintenance Therapy for Opiate Withdrawal","Inclusion Criteria:\n\n* Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.\n* Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg\u002F m2.\n* Willing to comply with the study requirements and to provide written informed consent.\n\nExclusion Criteria:\n\n* Infected with hepatitis B virus, hepatitis C virus, HIV.\n* Abuse of alcohol or drugs.\n* Use of other investigational drugs within 28 days prior to Day -5.\n* Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine\u002Fnaloxone as assigned maintenance therapy).\n* Other clinically significant medical conditions or laboratory abnormalities.",{"count":50,"type":22},32,[25],"Drug-drug interaction study between Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone",[54],"Healthy Volunteer Study","2026-07-15",{"date":57,"type":33},"2026-07-16",{"date":59,"type":33},"2025-01-07",{"date":61,"type":22},"2026-08",{"name":39,"class":40},3,""]